Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRY-box transcription factor 10 (SOX10) mRNA encodes a critical transcription factor belonging to the SOX family, which is essential for the development and maintenance of neural crest-derived lineages, including melanocytes, Schwann cells, and oligodendrocytes (UniProt P56817). In the context of oncology, SOX10 mRNA is frequently overexpressed in melanoma and certain gliomas, where it functions as a potent oncogene by driving cell proliferation, survival, and lineage plasticity (PubMed: 22751494). Because transcription factors like SOX10 are traditionally considered undruggable by small molecules due to their lack of defined ligand-binding pockets, targeting the SOX10 mRNA transcript has emerged as a viable therapeutic strategy. Experimental approaches utilize antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to induce the degradation of SOX10 mRNA or inhibit its translation, thereby reducing the levels of the SOX10 protein (PubMed: 24469057). This downregulation has been shown to inhibit tumor growth and sensitize melanoma cells to other therapies, such as BRAF inhibitors, in preclinical models. Mutations in the gene encoding this mRNA are also linked to genetic disorders like Waardenburg syndrome and Hirschsprung disease, highlighting its fundamental role in development (NIH/GARD). Therapeutic development faces significant challenges regarding the efficient delivery of nucleic acid-based drugs to solid tumors. Furthermore, there are concerns regarding potential adverse effects on healthy SOX10-dependent tissues, such as the peripheral nervous system and skin pigmentation. Current research is focused on optimizing delivery systems and identifying synergistic drug combinations to enhance the efficacy of SOX10 mRNA targeting.
Antisense-mediated mRNA degradation (RNase H-dependent) or RNA interference (RNAi) to prevent translation of the SOX10 protein.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRY-box transcription factor 10 (SOX10) mRNA (SOX10 mRNA).